Navigation Links
Octapharma USA Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
Date:1/11/2012

HOBOKEN, N.J., Jan. 11, 2012 /PRNewswire/-- Octapharma USA today announced that David E. Holliday has joined the biopharmaceutical company as Vice President of Commercial Development, assuming immediate responsibility for all U.S. product marketing, sales and commercial activities and coordination with global portfolio development initiatives.

(Photo:  http://photos.prnewswire.com/prnh/20120111/NY34235 )

Holliday is a senior executive with over 24 years of industry leadership experience, most recently serving as Vice President of Global Marketing Operations & Hemophilia with Baxter Bioscience. Holliday has extensive U.S. and international experience with particular expertise in management, commercial, sales, marketing and business development.

"We are very excited to have David Holliday, a true global leader in our industry, join our senior management team," said Octapharma USA President Flemming Nielsen. "David has critical leadership experience with major multinational pharmaceutical and biotech corporations. He joins Octapharma USA at an extremely important time for our company as our product portfolio in the U.S. will be increasing significantly in the next year and we expect David will be integral to our growth."

Holliday also served as Vice President, Global Marketing Operations and United Kingdom Business Unit Director during his eight years with Baxter Bioscience, which included a number of successful product launches. During his 17-year career with Novartis Pharmaceuticals and Ciba-Geigy Pharmaceuticals, Holliday held progressively responsible management positions, including Business Unit Director of the Transplantation and Mature Products Business Units in the UK.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for nearly 30 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [Human] 5%), is used to treat primary immune deficiencies, and Octapharma's Albumin (Human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® (Von Willebrand Factor/Coagulation Factor VIII Complex [Human]) received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of certain types of Von Willebrand Disease. Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com or www.wilateusa.com.


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Octapharma Announces octagam® 5% Again Available for U.S. Purchase
2. FDA Approves U.S. Market Return for octagam® Following Octapharmas Implementation of Enhanced Safety Measures
3. Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH
4. Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients
5. Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
6. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
7. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
8. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
11. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... and HONG KONG , Feb. 9, 2016 ... , PhD, has joined Athenex as Vice President of Corporate ... Raymond Yeung , MSc, MBA has joined as Senior Director ... Hong Kong . Simon Pedder ... that I have known for a while. Coupled together with ...
(Date:2/8/2016)... -- Cardiac Assist Devices - Medical ... Medical Devices sector report, " Cardiac Assist Devices ... an overview of Cardiac Assist Devices currently in ... on the pipeline products with comparative analysis of ... report reviews major players involved in the pipeline ...
(Date:2/8/2016)... 2016 Aesthetic Devices - Medical Devices Pipeline ... report, "Aesthetic Devices - Medical Devices Pipeline Assessment, 2015" ... stage. This report is prepared using ... by GlobalData,s team of industry experts. *Note: Certain ... based on the availability and relevance of data in ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator and developer ... vendors in the latest KLAS report, Population Health Management 2015: How Far Can Your ... for population health management (PHM). The latest KLAS Report, leveraging over 200 user ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Brain Preservation Foundation’s ... team from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), spearheaded by recent ... circuits of an intact rabbit brain for extremely long-term storage using a combination ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
(Date:2/8/2016)... ... February 08, 2016 , ... Coast Dental has a new way to help ... Month and family dentist Yvonne Dorrian, DMD, is hosting a free seminar on Friday, ... next to Target at 1207 North Peachtree Parkway in Peachtree City. Dr. Dorrian will ...
Breaking Medicine News(10 mins):